Movement Beyond Laxatives: Evolving Pharmacologic Options for IBS-C and CIC

Course overview

IBS-C and CIC are highly prevalent conditions that negatively impact Quality of Life and pose a significant economic burden on the healthcare system. Because so many patients self-treat the conditions, estimates of the number of Americans that suffer from IBS-C and CIC vary widely ranging from 2% to 27% of the population. Despite the $400 million dollars that are spent on laxatives each year, constipation still accounts for 2.5 million physician visits annually in the U.S. revealing a desperate need for improved patient counseling and knowledge of pharmacologic options beyond laxatives in pharmacies around the nation where millions of patients seek pharmacist recommendations. When traditional treatments, such as dietary manipulation and standard laxatives do not adequately treat or fail to treat IBS-C and CIC, pharmacists must be prepared to educate patients regarding the pharmacologic options available to relieve these frustrating and costly conditions.